tupungato / iStockphoto.com
12 July 2017Big Pharma
Actavis v Eli Lilly: UK Supreme Court updates patent infringement test
The UK Supreme Court has reformulated the three questions that should be asked when testing for equivalent patent infringement.
Already registered?
Login to your account
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
Biotechnology
16 July 2020 As the UK Supreme Court reverses a Court of Appeal decision relating to sufficiency, the ruling leaves patent applicants in a potentially difficult position, argues David Fyfield of Charles Russell Speechlys.
Big Pharma
7 July 2017 The UK Supreme Court has ruled that Actavis’s generic versions of cancer drug Alimta directly infringe patents owned by Eli Lilly, reversing two earlier decisions.
Americas
11 October 2018 Eli Lilly has filed a complaint against France-based biotechnology company Adocia over patents relating to fast-acting insulin.
Editor's picks
Editor's picks
Biotechnology
16 July 2020 As the UK Supreme Court reverses a Court of Appeal decision relating to sufficiency, the ruling leaves patent applicants in a potentially difficult position, argues David Fyfield of Charles Russell Speechlys.
Big Pharma
7 July 2017 The UK Supreme Court has ruled that Actavis’s generic versions of cancer drug Alimta directly infringe patents owned by Eli Lilly, reversing two earlier decisions.
Americas
11 October 2018 Eli Lilly has filed a complaint against France-based biotechnology company Adocia over patents relating to fast-acting insulin.
Biotechnology
16 July 2020 As the UK Supreme Court reverses a Court of Appeal decision relating to sufficiency, the ruling leaves patent applicants in a potentially difficult position, argues David Fyfield of Charles Russell Speechlys.
Big Pharma
7 July 2017 The UK Supreme Court has ruled that Actavis’s generic versions of cancer drug Alimta directly infringe patents owned by Eli Lilly, reversing two earlier decisions.
Americas
11 October 2018 Eli Lilly has filed a complaint against France-based biotechnology company Adocia over patents relating to fast-acting insulin.